Precigen’s PAPZIMEOS Receives Full FDA Approval as First Therapy for Adults with Recurrent Respiratory Papillomatosis
I'm PortAI, I can summarize articles.
Precigen Inc. announced that PAPZIMEOS™ (zopapogene imadenovec-drba) received full FDA approval in August 2025 as the first therapy for adults with recurrent respiratory papillomatosis (RRP). The approval is based on pivotal study results showing durable responses and reduced surgery needs among patients, with no new safety events reported during long-term follow-up. This marks a significant milestone for treatment options in RRP.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments